Vemurafenib induces senescence in acute myeloid leukemia and myelodysplastic syndrome by activating the HIPPO signaling pathway: implications for potential targeted therapy.
Qiao ZhouJiamin ZhangJingsong ZhangSimin LiangDuo CaiHan XiaoYu ZhuWenqiong XiangFernando Rodrigues-LimaJianxiang ChiFabien GuidezLi WangPublished in: Biology direct (2024)
Taken together, our findings demonstrate a significant upregulation of BRAF expression in AML and MDS patients, which is associated with unfavorable clinical outcomes. We also discovered that the BRAF inhibitor Vemurafenib induces cellular senescence through activation of the HIPPO signaling pathway. Analysis of BRAF expression holds promise as a prognostic indicator and potential therapeutic target for individuals with AML and MDS.
Keyphrases
- signaling pathway
- poor prognosis
- acute myeloid leukemia
- pi k akt
- end stage renal disease
- metastatic colorectal cancer
- epithelial mesenchymal transition
- dna damage
- newly diagnosed
- ejection fraction
- endothelial cells
- induced apoptosis
- wild type
- chronic kidney disease
- long non coding rna
- binding protein
- human health
- stress induced
- patient reported outcomes
- risk assessment
- big data
- deep learning
- climate change
- endoplasmic reticulum stress
- patient reported
- artificial intelligence